Cerebral amyloid angiopathy: diagnosis and potential therapies.

Abstract:

INTRODUCTION:Cerebral amyloid angiopathy (CAA) is characterized by the pathologic deposition of amyloid-beta within cortical and leptomeningeal arteries, arterioles, capillaries and, in rare cases, the venules of the brain. It is often associated with the development of lobar intracerebral hemorrhages (ICHs) but may cause other neurologic symptoms or be asymptomatic. Magnetic resonance imaging characteristics, such as lobar microbleeds, support a diagnosis of CAA and assist with hemorrhage risk assessments. Immunosuppressants are used to treat rarer inflammatory forms of CAA. For the more common forms of CAA, the use of antihypertensive medications can prevent ICH recurrence while the use of antithrombotics may increase hemorrhage risk. Anti-amyloid approaches to treatment have not yet been investigated in phase 3 trials. Areas covered: A literature search was conducted using MEDLINE on the topics of imaging, biomarkers, ICH prevention and treatment trials in CAA, focusing on its current diagnosis and management and opportunities for future therapeutic approaches. Expert commentary: There is likely a significant unrecognized burden of CAA in the elderly population. Continued research efforts to discover biomarkers that allow the early diagnosis of CAA will enhance the opportunity to develop treatment interventions.

journal_name

Expert Rev Neurother

authors

Weber SA,Patel RK,Lutsep HL

doi

10.1080/14737175.2018.1480938

subject

Has Abstract

pub_date

2018-06-01 00:00:00

pages

503-513

issue

6

eissn

1473-7175

issn

1744-8360

journal_volume

18

pub_type

杂志文章,评审
  • Precision medicine in genetic epilepsies: break of dawn?

    abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1253476

    authors: Reif PS,Tsai MH,Helbig I,Rosenow F,Klein KM

    更新日期:2017-04-01 00:00:00

  • Use of antiepileptic drugs in pregnancy.

    abstract::Babies born to mothers exposed to antiepileptic drugs (AEDs) are at increased risk for major congenital malformations, cognitive impairment and fetal death. For the millions of women with epilepsy, maintaining the safest drug that will successfully prevent seizures during pregnancy remains a primary consideration. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.7.1077

    authors: Tatum WO

    更新日期:2006-07-01 00:00:00

  • Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice.

    abstract::Introduction: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.Areas covered: The authors review the effect of pregnancy and the postpartum period on the cours...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1743684

    authors: Sharma V,Sharma P,Sharma S

    更新日期:2020-04-01 00:00:00

  • Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies.

    abstract:INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194203

    authors: Amanatkar HR,Papagiannopoulos B,Grossberg GT

    更新日期:2017-01-01 00:00:00

  • Internet-supported versus face-to-face cognitive behavior therapy for depression.

    abstract::Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.2015.1125783

    authors: Andersson G,Topooco N,Havik O,Nordgreen T

    更新日期:2016-01-01 00:00:00

  • Effect of second-generation antipsychotics on cognition: current issues and future challenges.

    abstract::Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.143

    authors: Hill SK,Bishop JR,Palumbo D,Sweeney JA

    更新日期:2010-01-01 00:00:00

  • CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine.

    abstract::Cortical spreading depression (CSD) has been at the center stage of migraine pathophysiology for approximately six decades. Reanalysis of CSD reveals several major unbridgeable gaps in this experimental neurophysiologic concept for migraine. Key phenotypic and pharmacological features of migraine challenge the assumed...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.103

    authors: Gupta VK

    更新日期:2009-11-01 00:00:00

  • Craniomandibular muscles, intraoral orthoses and migraine.

    abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.3.371

    authors: Shevel E

    更新日期:2005-05-01 00:00:00

  • Fear reduction in patients with chronic pain: a learning theory perspective.

    abstract::Acute pain informs the individual that there is an imminent threat of body damage, and is associated with the urge to escape and avoid. Fear learning takes place when neutral stimuli receive the propensity to predict the occurrence of pain, and when defensive responses are initiated in anticipation of potential threat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.115

    authors: den Hollander M,de Jong JR,Volders S,Goossens ME,Smeets RJ,Vlaeyen JW

    更新日期:2010-11-01 00:00:00

  • Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1028370

    authors: Rizzo R,Martino D

    更新日期:2015-04-01 00:00:00

  • Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.

    abstract::Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migrain...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.41

    authors: Freitag FG

    更新日期:2011-04-01 00:00:00

  • Rivastigmine for Alzheimer's disease.

    abstract::Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families. Rivastigmine is a powerful slow-reversible, noncompetitive carbamate cholinesterase inhibitor that is approved for the treatment of mild-to-moderate Alzheimer's diseas...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.5.563

    authors: Desai AK,Grossberg GT

    更新日期:2005-09-01 00:00:00

  • Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.

    abstract::With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.3.357

    authors: Bergamaschi R

    更新日期:2006-03-01 00:00:00

  • Cognitive and behavioral assessment in Parkinson's disease.

    abstract::Introduction: Cognitive impairment and behavioral disturbances are common findings in Parkinson's disease (PD). Despite initially being considered late complications of the disease, it is currently accepted that almost all PD patients will exhibit cognitive and behavioral abnormalities from the early and even the prem...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1629290

    authors: Martinez-Horta S,Horta-Barba A,Kulisevsky J

    更新日期:2019-07-01 00:00:00

  • Metabolic treatments of migraine.

    abstract::Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may no...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1729130

    authors: Lisicki M,Schoenen J

    更新日期:2020-03-01 00:00:00

  • Paroxysmal movement disorders - practical update on diagnosis and management.

    abstract::Introduction: Paroxysmal dyskinesias and episodic ataxias are often caused by mutations in genes related to cell membrane and synaptic function. Despite the exponential increase in publications of genetically confirmed cases, management remains largely clinical based on non-systematic evidence. Areas covered: The auth...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648211

    authors: De Gusmao CM,Silveira-Moriyama L

    更新日期:2019-09-01 00:00:00

  • Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.

    abstract::Alzheimer's disease (AD) is a prevalent and currently incurable brain disease whose impact will continue to rise as the population ages. With limited treatment options, a variety of experimental therapies are currently in clinical trials. EVP-6124 (encenicline) is an α7 nicotinic acetylcholine receptor partial agonist...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.995639

    authors: Deardorff WJ,Shobassy A,Grossberg GT

    更新日期:2015-01-01 00:00:00

  • Lessons learned in the abuse of pain-relief medication: a focus on healthcare costs.

    abstract::The increasing prevalence of chronic pain with its major societal impact and the escalating use of opioids in managing it, along with their misuse, abuse, associated fatalities and costs, are epidemics in modern medicine. Over the past two decades, multiple lessons have been learned addressing various issues of abuse....

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.13.33

    authors: Manchikanti L,Boswell MV,Hirsch JA

    更新日期:2013-05-01 00:00:00

  • Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease.

    abstract::Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.194

    authors: Han C,Shim DS,Lee SJ,Patkar AA,Masand PS,Pae CU

    更新日期:2012-02-01 00:00:00

  • Technology-based assessment of motor and nonmotor phenomena in Parkinson disease.

    abstract:INTRODUCTION:The increasing development and availability of portable and wearable technologies is rapidly expanding the field of technology-based objective measures (TOMs) in neurological disorders, including Parkinson disease (PD). Substantial challenges remain in the recognition of disease phenomena relevant to patie...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2018.1530593

    authors: Merola A,Sturchio A,Hacker S,Serna S,Vizcarra JA,Marsili L,Fasano A,Espay AJ

    更新日期:2018-11-01 00:00:00

  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Stem cell therapy for Parkinson's disease.

    abstract::The aim of stem cell therapy for Parkinson's disease is to reconstruct nigro-striatal neuronal pathways using endogenous neural stem/precursor cells or grafted dopaminergic neurons. As an alternative, transplantation of stem cell-derived dopaminergic neurons into the striatum has been attempted, with the aim of stimul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.6.667

    authors: Takahashi J

    更新日期:2007-06-01 00:00:00

  • Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon.

    abstract::In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章,评审

    doi:10.1586/14737175.4.4.613

    authors: Di Napoli M,Papa F

    更新日期:2004-07-01 00:00:00

  • Current concept of anxiety: implications from Darwin to the DSM-V for the diagnosis of generalized anxiety disorder.

    abstract::This article proposes a revision of the historical evolution of the concepts of generalized anxiety disorder (GAD). Currently, Darwin's evolutionary theory is the hegemonic paradigm for modern science and influences research on mental disorders. Throughout the 20th Century, the editions of the Diagnostic and Statistic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.101

    authors: Coutinho FC,Dias GP,do Nascimento Bevilaqua MC,Gardino PF,Pimentel Rangé B,Nardi AE

    更新日期:2010-08-01 00:00:00

  • Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.

    abstract::The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.5.737

    authors: Kornstein SG

    更新日期:2008-05-01 00:00:00

  • Acute ischemic stroke management: concepts and controversies.A narrative review.

    abstract:INTRODUCTION:Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still suffering from complications and stroke recurrence, more questions have been raised as to how we can better i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1836963

    authors: Li KHC,Jesuthasan A,Kui C,Davies R,Tse G,Lip GYH

    更新日期:2021-01-01 00:00:00

  • Medical marijuana in neurology.

    abstract::Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.985209

    authors: Benbadis SR,Sanchez-Ramos J,Bozorg A,Giarratano M,Kalidas K,Katzin L,Robertson D,Vu T,Smith A,Zesiewicz T

    更新日期:2014-12-01 00:00:00

  • Treatments for generalized anxiety disorder.

    abstract::Generalized anxiety disorder is characterized by excessive chronic anxiety in association with many somatic symptoms. The disorder has pervasive effects on quality of life, including work, social and educational aspects and requires long-term therapy. Available studies in patients are the Diagnostic and Statistical Ma...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.2.285

    authors: Struzik L,Vermani M,Coonerty-Femiano A,Katzman MA

    更新日期:2004-03-01 00:00:00

  • Assessment, pathophysiology and treatment of fatigue in multiple sclerosis.

    abstract::This review will update current views of the physiopathology and treatment of fatigue in multiple sclerosis. Fatigue is a common symptom in multiple sclerosis, being reported by about a third of the patients. For many of them it is the most disabling symptom, with negative consequences on working activity and daily li...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.6.867

    authors: Comi G,Leocani L

    更新日期:2002-11-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00